Summary: Genmab has won the 2007 Scrip Biotech Company of the Year award.
Copenhagen, Denmark; December 5, 2007 - Genmab A/S (OMX: GEN) announced today it
has won the 2007 Scrip Biotech Company of the Year award. The award was
presented December 4, 2007 at an awards ceremony and gala dinner at the London
Hilton on Park Lane hotel.
The award recognizes Genmab's accomplishments during 2006 and 2007 including our
work to bring new products closer to their first markets, raise capital, enter
significant licensing agreements, maintain strong management, address unmet
medical needs through development of our new technology UniBody(R) and to
transform Genmab from an early stage to a more mature world leading
biotechnology company.
“Receiving the Scrip Award is a testament to the skill and efficiency of all
Genmab employees who have worked hard to make our business grow. We are
delighted to have won and are honored to receive this year's Scrip Award for
Biotech Company of the Year,” said Lisa N. Drakeman, Ph.D., Chief Executive
Officer at Genmab.
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for unmet medical needs. Using unique,
cutting-edge antibody technology, Genmab's world class discovery and development
teams have created and developed an extensive pipeline of products for potential
treatment of a variety of diseases including cancer and autoimmune disorders.
As Genmab advances towards a commercial future, we remain committed to our
primary goal of improving the lives of patients who are in urgent need of new
treatment options. For more information on Genmab's products and technology,
visit www.genmab.com.
This press release contains forward looking statements. The words “believe”,
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical
trials including unforeseen safety issues, uncertainties related to product
manufacturing, the lack of market acceptance of our products, our inability to
manage growth, the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. Genmab is
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to
actual results, unless this is required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);
HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);
and UniBody(R) are all trademarks of Genmab A/S.
Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M:
+45 25 27 47 13, E: hth@genmab.com
Investor News No. 16/2007
###
